Efficacy of liposomal amphotericin B with prolonged circulation in blood in treatment of severe pulmonary aspergillosis in leukopenic rats by Etten, E.W.M. (Els) van et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY,
0066-4804/00/$04.0010
Mar. 2000, p. 540–545 Vol. 44, No. 3
Copyright © 2000, American Society for Microbiology. All Rights Reserved.
Efficacy of Liposomal Amphotericin B with Prolonged
Circulation in Blood in Treatment of Severe Pulmonary
Aspergillosis in Leukopenic Rats
ELS W. M. VAN ETTEN,* LORNA E. T. STEARNE-CULLEN, MARIAN T. TEN KATE,
AND IRMA A. J. M. BAKKER-WOUDENBERG
Department of Medical Microbiology & Infectious Diseases, Erasmus University Medical
Center Rotterdam, Rotterdam, The Netherlands
Received 5 February 1999/Returned for modification 17 August 1999/Accepted 1 December 1999
The therapeutic efficacy of long-circulating polyethylene glycol-coated liposomal amphotericin B (AMB)
(PEG-AMB-LIP) was compared with that of AMB desoxycholate (Fungizone) in a model of severe invasive
pulmonary aspergillosis in persistently leukopenic rats as well as in temporarily leukopenic rats. PEG-AMB-
LIP treatment (intravenous administration) consisted of a single, or double (every 72 h), or triple (every 72 h)
dose of 10 mg of AMB/kg of body weight, a double dose (every 72 h) of 14 mg of AMB/kg, or a 5-day treatment
(every 24 h) with 6 mg/kg/dose. AMB desoxycholate was administered for 10 consecutive days at 1 mg of
AMB/kg/dose. Treatment was started 30 h after fungal inoculation, at which time mycelial growth was firmly
established. Both persistently and temporarily leukopenic rats died between 4 and 9 days after Aspergillus
fumigatus inoculation when they were left untreated or after treatment with a placebo. In persistently leuko-
penic rats, a single dose of PEG-AMB-LIP (10 mg/kg) was as effective as the 10-day treatment with AMB
desoxycholate (at 1 mg/kg/dose) in significantly prolonging the survival of rats infected with A. fumigatus and
in reducing the dissemination of A. fumigatus to the liver. Prolongation of PEG-AMB-LIP treatment (double or
triple dose or 5-day treatment) did not further improve efficacy. For temporarily leukopenic rats no major
advances in efficacy were achieved compared to those for persistently leukopenic rats, probably because the
leukocyte numbers in blood were restored too late in the course of infection.
Because a high rate of mortality from pulmonary aspergil-
losis continues to be seen for leukopenic patients, despite
aggressive antifungal therapy, there is an urgent need for
therapeutic advances (10). At present three lipid formula-
tions of amphotericin B (AMB) are industrially produced:
Abelcet (The Liposome Company, Inc.), Amphocil or Ampho-
tec (SEQUUS Pharmaceuticals, Inc.), and AmBisome (NeX-
star Pharmaceuticals, Inc.). Although it is clear from a number
of clinical studies that all three AMB-lipid formulations are
substantially less toxic than AMB desoxycholate (Fungizone),
it is still too early to draw sharp conclusions on the optimal
dosing of these AMB-lipid formulations in the treatment of
invasive pulmonary aspergillosis (4, 7, 11, 13, 14, 16–18, 21,
29–34).
Experimental studies on the efficacy of systemic treatment
with these three AMB-lipid formulations have been performed
with different animal models of invasive aspergillosis (2, 9, 12,
13, 15, 19, 20, 23, 28). In only two of these models, one with
rabbits (2, 12, 28) and another with rats (15), the respiratory
route of infection and profound and persistent granulocytope-
nia were part of the experimental design. In these two models
improved survival of animals after multidose treatment with
Amphocil (2, 28) or AmBisome (12, 15) compared to that after
treatment with AMB desoxycholate has been reported.
It is evident that the three AMB-lipid formulations have
quite different structural and pharmacokinetic characteristics
(13). Abelcet and Amphocil are rapidly taken up from the
blood by phagocytic cells of the mononuclear phagocyte system
(MPS) in the liver and spleen, resulting in relatively low AMB
concentrations in blood compared to those of AMB desoxy-
cholate when the two formulations are given at equivalent
doses. AmBisome consists of small rigid liposomes that remain
in the circulation for a relatively prolonged period of time.
With AmBisome, the concentrations of AMB in blood are
increased compared to those achieved with AMB desoxy-
cholate given at an equivalent dose. For AmBisome, the blood
residence time is primarily dependent on the dose adminis-
tered (12, 24). At a dose of 7 mg of AMB/kg of body weight the
elimination half-life of AmBisome in mice is about 8 h (24).
At our laboratory a new type of liposomal AMB, in which
AMB is complexed to a hydrophilic phospholipid derivative of
polyethylene glycol 1900 (PEG), was prepared and is desig-
nated PEG-AMB-LIP (25). Incorporation of PEG-derivatized
distearoylphosphatidylethanolamine (PEG-DSPE) results in a
hydrophilic PEG coating on the surface of the liposomes, to
which binding of blood proteins is substantially reduced. As a
result, uptake of liposomes by the MPS is substantially avoided
and a relatively long blood residence time of intact liposomes
is achieved, with the residence time being independent of the
dose administered (35). For PEG-AMB-LIP the elimination
half-life in mice was shown to be approximately 20 h for a dose
range of 0.5 to 9 mg of AMB/kg (25, 26).
This prolonged blood residence time of PEG-AMB-LIP may
be important to obtain increased concentrations of liposomal
AMB at sites of fungal infection outside the MPS, such as the
kidneys and lungs. The superior efficacy of PEG-AMB-LIP
compared with that of AmBisome after treatment with a single
dose was previously demonstrated in our model of severe in-
vasive Candida albicans infection (26, 27), in which the kidney
is the most severely infected organ. With respect to the treat-
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ment of pulmonary infections, it has been shown in our labo-
ratory that PEG-containing liposomes selectively localize at
the site of Klebsiella pneumoniae-infected lung tissue (5), re-
sulting in an improved efficacy of gentamicin or ceftazidime
entrapped in such long-circulating liposomes (6). An improved
efficacy of PEG-containing AMB liposomes (19) having a lipid
composition different from that of PEG-AMB-LIP was re-
cently demonstrated against invasive pulmonary aspergillosis
in mice when efficacy was compared to that of AmBisome.
Further improvement of efficacy was observed when monoclo-
nal antibodies directed to the luminal surface of the pulmonary
vessel wall in the mouse lung were attached to these PEG-
containing AMB liposomes. In that study (19) only temporary
immunosuppression was applied, and treatment was started
very early (2 h) after fungal inoculation.
In the present study the efficacies of single- or multiple-dose
treatment with PEG-AMB-LIP were compared with that of
AMB desoxycholate in the treatment of severe invasive pul-
monary aspergillosis in persistently as well as temporarily leu-
kopenic rats, in which treatment was started at the time that
fungal infection was firmly established (30 h after fungal inoc-
ulation).
MATERIALS AND METHODS
Animals. Female R strain albino rats (specified pathogen free; age, 18 to 25
weeks; weight, 185 to 225 g) were obtained from Harlan CPB (Austerlitz, The
Netherlands).
Materials. Sabouraud dextrose agar (SDA) was from Unipath Ltd. (Basing-
stoke, England). AMB and AMB desoxycholate were kindly provided by Bristol
Myers-Squibb, Woerden, The Netherlands. Hydrogenated soybean phosphati-
dylcholine (HSPC) and PEG-DSPE were obtained from Avanti Polar Lipids, Inc.
(Alabaster, Ala.). Dimethyl sulfoxide (DMSO) was from Janssen Chimica (Til-
burg, The Netherlands). Cyclophosphamide and cholesterol (Chol) were from
Sigma (St. Louis, Mo.). Chloroform and methanol were from Merck (Darmstadt,
Germany).
Liposome preparation. PEG-DSPE–HSPC–Chol–AMB in a molar ratio of
0.21:1.79:1:0.32 (PEG-AMB-LIP) and placebo liposomes (liposomes devoid of
AMB) were prepared as described previously (25, 26). Briefly, AMB was com-
plexed to PEG-DSPE in chloroform-methanol (1:1; vol/vol) at 65°C, followed by
the addition of HSPC and Chol. This lipid mixture was evaporated to dryness and
was subsequently hydrated by vortex mixing in a buffer solution containing 10
mM sodium succinate and 10% (wt/vol) sucrose (pH 5.5) at 65°C. The phospho-
lipid concentration was determined by a phosphate assay (3). The AMB concen-
tration was determined spectrophotometrically at 405 nm, after destruction of
the liposomes in DMSO-methanol (1/1; vol/vol).
Aspergillus strain. A clinical isolate of Aspergillus fumigatus from an immuno-
compromised patient with invasive pulmonary aspergillosis was used. The MIC
and minimal fungicidal concentration of AMB for the isolate are 0.4 and 0.8
mg/liter, respectively (15). This strain was stored under oil on SDA. At least once
every 2 months the strain was passed through a rat to maintain its virulence. For
inoculation a suspension of A. fumigatus conidia in sterile saline was prepared as
described previously (15).
Immunosuppression and supportive care. The first series of experiments was
performed with persistently leukopenic rats. Granulocytopenia (,0.5 3 109
granulocytes/liter) from the time of A. fumigatus inoculation to termination of
the study was obtained by intraperitoneal administration of cyclophosphamide at
90 mg/kg starting 5 days before A. fumigatus inoculation (day 25), followed by
administration of additional doses of 60 mg/kg on the day before inoculation (day
21) and at 4-day intervals thereafter (day 3 and day 7) (15). In a second series
of experiments cyclophosphamide was given up to day 3 in order to obtain
temporary leukopenia. To prevent bacterial superinfection, strict hygienic care
was applied, and rats received ciprofloxacin (660 mg/liter) and polymyxin E (100
mg/liter) in their drinking water during the whole experiment. From the day
before inoculation, intramuscularly administered amoxicillin (40 mg/kg/dose)
was added to this regimen daily for the remainder of the experiment. Shortly
before and after inoculation, gentamicin (40 mg/kg/dose) was administered in-
tramuscularly.
Experimental lung infection. Experimental pulmonary aspergillosis was ob-
tained as described previously (15). Briefly, rats were anesthetized, after which
the left main bronchus was intubated and the left lung was inoculated with 0.02
ml of a suspension containing 2 3 104 conidia.
Efficacies of PEG-AMB-LIP and AMB desoxycholate in leukopenic rats in-
fected with A. fumigatus. The left lobes of the lungs of leukopenic rats were
inoculated with A. fumigatus at time zero. Groups of 15 animals each were
treated intravenously with PEG-AMB-LIP or AMB desoxycholate. PEG-AMB-
LIP treatment consisted of a single or double (every 72 h) dose of 10 mg of
AMB/kg or a double dose (every 72 h) of 14 mg of AMB/kg. AMB desoxycholate
was administered for 10 consecutive days (every 24 h) at 1 mg of AMB/kg/dose.
In two additional groups of five rats each, treatment with PEG-AMB-LIP three
times (every 72 h) with 10 mg of AMB/kg/dose or for 5 consecutive days (every
24 h) with 6 mg/kg/dose was investigated. No toxicity in terms of acute death
directly after treatment was observed for any of the treatment regimens. Controls
were treated with placebo liposomes or 5% glucose or were left untreated.
Treatment was started 30 h after fungal inoculation, at which time mycelial
growth was firmly established by histopathologic examination (periodic acid-
Schiff staining). Survival was recorded daily for each rat. At the postmortem
examination, the left and right lungs and the liver were removed and were
processed for the determination of viable A. fumigatus counts, as described
previously for C. albicans (26). The following criteria were used to assess the
efficacy of treatment: survival of rats up to 12 days after A. fumigatus inoculation,
the presence of viable A. fumigatus organisms in the left lung, and the presence
of dissemination to the right lung and liver at the time of death.
Determination of leukocyte counts in blood of leukopenic rats infected with A.
fumigatus. Two separate groups of 15 rats each were immunosuppressed with
cyclophosphamide up to either day 3 or day 7 after A. fumigatus inoculation, as
described above, and were treated twice (every 72 h) with PEG-AMB-LIP at 10
mg of AMB/kg/dose. The total numbers of leukocytes in the blood of the
surviving rats were determined with an automatic blood cell counter (COBAS
MINOS STEX; ABX Hematology, Montpeiller, France). Blood samples were
obtained by orbital puncture while the rats were under light CO2 anesthesia. The
percentages of granulocytes were derived from differential counts of leukocytes
in cytospin preparations of buffy coats.
Statistical analysis. Statistical evaluation of differences in survival (Kaplan-
Meier plot) was performed by the log rank test. This test examines the decrease
in survival with time as well as the final percentage of surviving rats. Differences
in the numbers of rats with A. fumigatus in the left lung and the numbers of rats
with A. fumigatus dissemination to the right lung and liver at the time of death
were examined by Fisher’s exact test. P values of #0.05 were considered signif-
icant in these analyses.
RESULTS
Efficacy of treatment in persistently leukopenic rats. The
effects of treatment on survival of persistently leukopenic rats
with pulmonary aspergillosis and on the presence of viable A.
fumigatus in the left lung, right lung, and liver at the time of
death are shown in Fig. 1 and Table 1, respectively. In this
model of pulmonary aspergillosis, untreated rats as well as
placebo-treated rats died between 4 and 9 days after inocula-
tion. Postmortem cultures of samples from these rats revealed
that at the time of death the infection had disseminated to the
right lung and liver in the majority of rats. Treatment with a
single dose of PEG-AMB-LIP (10 mg of AMB/kg) resulted in
significantly prolonged (P # 0.005) survival (Fig. 1a) and sig-
nificantly less (P # 0.005) dissemination to the liver (Table 1)
compared to those that resulted from placebo treatment. Sim-
ilar results were obtained after two treatments with either 10 or
14 mg of AMB/kg/dose (Fig. 1b and Table 1, respectively) or
after more prolonged treatment (three 10-mg/kg doses, with
doses given every 72 h) or more intensive treatment early in the
course of infection (five 6-mg/kg doses, with doses given every
24 h) (data not shown). Treatment with AMB desoxycholate
for 10 consecutive days at 1 mg of AMB/kg/dose resulted in
significantly prolonged (P # 0.05) survival (Fig. 1c) and signif-
icantly less dissemination to the right lung (P # 0.05) as well as
to the liver (P # 0.005) (Table 1) compared to those that
resulted from placebo treatment. When the different treatment
regimens were compared with each other, no significant dif-
ferences in efficacy were observed.
Toxicity in terms of death or renal or hepatic dysfunction
was not observed after treatment with PEG-AMB-LIP (2 doses
of 14 mg of AMB/kg) or AMB desoxycholate (10 doses of 1 mg
of AMB/kg) in uninfected rats that were rendered leukopenic
with cyclophosphamide and that received antibiotics for the
prevention of bacterial superinfections (data not shown).
Efficacy of treatment in temporarily leukopenic rats. The
effects of treatment on survival of temporarily leukopenic rats
with pulmonary aspergillosis and on the presence of viable A.
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fumigatus organisms in the left lung, right lung, and liver at the
time of death are shown in Fig. 2 and Table 1, respectively.
Untreated rats as well as placebo-treated rats still died be-
tween 4 and 9 days after inoculation, with dissemination to the
right lung and liver in the majority of rats. Treatment with a
single dose of PEG-AMB-LIP (10 mg of AMB/kg) resulted in
significantly prolonged (P # 0.005) survival (Fig. 2a) and sig-
nificantly less (P # 0.05) dissemination to the liver (Table 1)
compared to those that resulted from placebo treatment. For
PEG-AMB-LIP similar results were obtained after two treat-
ments with either 10 or 14 mg of AMB/kg/dose (Fig. 2b and
Table 1, respectively) or after more prolonged treatment
(three 10-mg/kg doses, with doses given every 72 h) or more
intensive treatment early in the course of infection (five
6-mg/kg doses, with doses given every 24 h) (data not shown).
After two treatments with PEG-AMB-LIP at 10 mg of AMB/
kg/dose, survival was significantly more prolonged in tempo-
rarily leukopenic rats than in persistently leukopenic rats (P #
0.05). Treatment with AMB desoxycholate for 10 consecutive
days at 1 mg of AMB/kg/dose resulted in significantly pro-
longed (P # 0.005) survival (Fig. 2c) and significantly less
dissemination to the right lung (P # 0.005) as well as to the
liver (P # 0.005) (Table 1) compared to those that resulted
from placebo treatment.
Number of leukocytes in blood of leukopenic rats infected
with A. fumigatus. Persistently leukopenic rats immunosup-
pressed with cyclophosphamide up to day 7 after A. fumigatus
inoculation and treated with a double dose of PEG-AMB-LIP
at 10 mg of AMB/kg/dose are profoundly leukopenic from the
time of A. fumigatus inoculation (time zero) up to 12 days after
inoculation, during which time the mean leukocyte count is
,0.6 3 109/liter (data not shown). Differential counts showed
that less than 10% of the leukocytes consisted of granulocytes.
The total numbers of leukocytes in the blood of temporarily
leukopenic rats immunosuppressed with cyclophosphamide up
to day 3 after A. fumigatus inoculation were determined in rats
that were treated with a double dose of PEG-AMB-LIP at 10
mg of AMB/kg/dose. Surviving rats are profoundly leukopenic
from the time of A. fumigatus inoculation (time zero) up to 7
days after inoculation. From day 9 after inoculation a substan-
tial rise in leukocyte numbers is observed, with the mean num-
bers of leukocytes being 0.7 3 109/liter at day 9 (with 5 of 15
rats surviving), 8.0 3 109/liter at day 11 (with 3 of 15 rats
surviving), and 13.7 3 109/liter at day 13 (with 3 of 15 rats
surviving), which is a twofold increased level compared to
normal values (mean value, 6.5 3 109/liter).
DISCUSSION
The importance of invasive aspergillosis has progressively
increased, and as a result it is now a major direct or contrib-
utory cause of death at leukemia treatment centers and bone
marrow transplantation and solid-organ transplantation cen-
ters (10). In the present study the efficacy of PEG-AMB-LIP,
which has a prolonged circulation in blood, was compared to
that of AMB desoxycholate in a rat model of severe pulmonary
aspergillosis. The same animal model was previously used to
investigate the efficacy of a lipid formulation of AMB (AmBi-
some) versus that of AMB desoxycholate (15). Clinically rele-
vant issues are addressed with this animal model, such as
profound and persistent leukopenia, with inoculation of A.
fumigatus via the respiratory route resulting in a one-sided
pulmonary infection with dissemination to the right lung and to
the liver during the course of infection and with infiltration of
pulmonary tissue by hyphae with angioinvasion. In the present
study treatment was started when hyphal growth was firmly
established. It is known from clinical experience that persistent
leukopenia, histological evidence of angioinvasion, and de-
layed therapy are important factors that predict a poor re-
sponse to treatment (10). The experimental setup in the
present study was deliberately chosen, as we wanted to inves-
tigate the potential of PEG-AMB-LIP under very severe cir-
cumstances.
In persistently leukopenic rats survival was significantly pro-
longed after administration of only a single dose of PEG-
FIG. 1. Effects of a single dose (a) or double doses (b) of PEG-AMB-LIP
versus multiple doses of AMB desoxycholate (c) on survival of persistently
leukopenic rats with pulmonary aspergillosis (Kaplan-Meier plot). Leukopenic
rats were inoculated in the left lobe of the lung with 2 3 104 A. fumigatus conidia
at time zero. Groups of 15 animals each were treated intravenously with PEG-
AMB-LIP as a single dose of 10 mg of AMB/kg (n ), a double dose (given every
72 h) of 10 mg of AMB/kg/dose (}) or a double dose (given every 72 h) of 14 mg
of AMB/kg/dose (); AMB desoxycholate was administered for 10 consecutive
days at 1 mg of AMB/kg/dose (F). Controls were treated with placebo liposomes
() or 5% glucose (E) or were left untreated (). Treatment was started 30 h
after fungal inoculation, at which time mycelial growth was firmly established.
[, P # 0.05; and p, P # 0.005, versus untreated or placebo-treated rats.
542 VAN ETTEN ET AL. ANTIMICROB. AGENTS CHEMOTHER.
AMB-LIP. Similar results were obtained after the 10-day treat-
ment with AMB desoxycholate. It should be stated that
although the survival of the rats was significantly prolonged,
treatment did not result in eradication of the infection, and
eventually, a high rate of mortality was still observed at day 12
after A. fumigatus inoculation.
The results for AMB desoxycholate with respect to the sur-
vival of rats confirm previous results (15). The survival of rats
after treatment with a single dose of PEG-AMB-LIP is also
very similar to the survival after a 10-day treatment with Am-
Bisome (10 mg/kg/dose) in the same animal model (15).
In the present study the dissemination of A. fumigatus to the
right lung and liver was reduced after AMB desoxycholate
treatment, whereas this was not observed in the previous study
(15). In our view daily administration of AMB desoxycholate
may help to prevent hematological fungal dissemination, and
therefore, the conclusion from Leenders et al. (15) that Am-
Bisome was more effective than AMB desoxycholate in reduc-
ing the degree of dissemination of unilateral pulmonary as-
pergillosis should now be reconsidered. The degree of
dissemination of A. fumigatus to the liver was also significantly
reduced by PEG-AMB-LIP treatment, even after only a single
dose. Evidently, mortality did not seem to directly correlate
with the degree of dissemination of infection, as was also
remarked by Leenders et al. (15). In fact, we still do not know
the exact cause of death in this animal model. It is presently
under investigation whether the animals die from respiratory
insufficiency resulting from vascular involvement of the left
lung or from toxins produced by the fungus.
To investigate whether the efficacy of PEG-AMB-LIP could
be further improved, treatment with a double or a triple dose
of 10 mg/kg/day was examined. The dosing interval of 72 h was
chosen because of the prolonged elimination half-life of PEG-
AMB-LIP (approximately 20 h) (25, 26) in comparison to that
of AmBisome (about 8 h) (24), for which a dosing interval of
24 h was previously chosen by Leenders et al. (15). PEG-AMB-
LIP was also administered at a double dose of 14 mg/kg/day,
being the maximum dose tolerated by these infected rats
(acute death immediately after administration was observed
with higher dosages). As untreated rats had already died by 4
days after A. fumigatus inoculation, a more intensive treatment
early in the course of infection was also investigated. When
PEG-AMB-LIP was administered for 5 consecutive days, acute
toxicity was observed during treatment with 10 mg/kg/day. The
daily dose was reduced to 6 mg/kg, which was the maximum
tolerated dose for this intensive treatment regimen.
In persistently leukopenic rats prolongation of PEG-AMB-
LIP treatment (double or triple doses or 5-day treatment) did
not further improve its efficacy. Apparently, the initial delay in
the progression of infection that was obtained after treatment
with a single dose of PEG-AMB-LIP could not be further
extended. These results cannot readily be explained, mainly
because of our lack of understanding of the exact means of
pathogenesis and the cause of death in this animal model.
Another issue is that endpoints based on survival and culture-
positive organs at the time of death may be too austere to allow
detection of differences in response to antifungal therapy. In a
model of severe pulmonary aspergillosis in profoundly leuko-
penic rabbits (2, 12, 28), markers of fungus-mediated tissue
injury (pulmonary lesion scores and lung weight scores) and
levels of galactomannan in serum or D-mannitol in bronchoal-
veolar lavage fluid were also used as parameters for determi-
nation of antifungal efficacy. Whether these markers can also
be applied in our rat model of pulmonary aspergillosis is under
investigation.
From clinical experience it is known that bone marrow re-
covery and increasing numbers of leukocytes in blood are cru-
cial factors in the outcome of treatment (10). In the second
part of the study it was investigated whether the prolongation
of survival observed after antifungal treatment in persistently
leukopenic rats was sufficient enough to keep the animals alive
when the numbers of leukocytes in blood were restored late in
the course of infection (temporarily leukopenic rats). Unfor-
tunately, no major advances in efficacy were achieved in tem-
porarily leukopenic rats compared to that achieved with per-
sistently leukopenic rats. The total numbers of leukocytes in
blood were determined for a separate group of temporarily
immunosuppressed rats infected with A. fumigatus and treated
with the optimal treatment regimen (double dose of PEG-
AMB-LIP). Untreated rats could not be used for this purpose,
as all animals had ultimately died at day 9. In the treated rats
a substantial rise in leukocyte numbers was observed from day
9. At that time point only 33% (5 of 15) of the animals were
still alive. It was remarkable that from these 5 rats only the rats
with the highest leukocyte counts (3 of 15) eventually survived.
From these data it is concluded that the leukocyte numbers in
TABLE 1. Effects of a single dose or double doses of PEG-AMB-LIP versus multiple doses of AMB desoxycholate on presence of viable A.
fumigatus in the left lung and dissemination to the right lung and liver at the time of death in persistently or temporarily leukopenic ratsa
Treatmentb Daily dose of AMB(mg/kg)
No. of doses
(dosing interval [h])
No. of culture-positive organsc/total no. of ratsd
Left lung Right lung Liver
P T P T P T
Untreated 15/15 15/15 14/15 12/15 10/15 9/15
PEG-AMB-LIP 10 1 15/15 15/15 13/15 12/15 1/15e 2/15f
PEG-AMB-LIP 10 2 (72) 15/15 15/15 9/15 8/15 0/15e 0/15e
PEG-AMB-LIP 14 2 (72) 15/15 15/15 9/15 8/15 0/15e 0/15e
AMB desoxycholate 1 10 (24) 15/15 15/15 9/15f 6/15e 1/15e 1/15e
Placebo liposomes 2 (72) 15/15 15/15 12/15 12/15 11/15 8/15
Placebo (glucose) 10 (24) 15/15 15/15 15/15 14/15 10/15 8/15
a Leukopenic rats were inoculated in the left lung at time zero with 2 3 104 A. fumigatus conidia.
b PEG-AMB-LIP, AMB desoxycholate, or placebo treatment was administered intravenously.
c Effect of treatment was determined by postmortem cultures.
d P, persistent leukopenia; T, temporary leukopenia.
e P # 0.005 versus placebo treatment.
f P # 0.05 versus placebo treatment.
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blood were restored too late in the course of the infection to
have a significant effect on the outcome of treatment. It seems
to be very worthwhile to investigate the effect of treatment
when the numbers of leukocytes are rising from day 5 after A.
fumigatus inoculation, at which time point the majority of rats
are still alive.
In our opinion the therapeutic options of PEG-AMB-LIP in
pulmonary aspergillosis need to be further explored, e.g., the
effect of earlier (empirical) treatment. Another option might
be local administration of PEG-AMB-LIP via aerosol inhala-
tion. Two different experimental studies have been published
on the effect of prophylaxis of pulmonary aspergillosis with
aerosolized AmBisome (1) or Abelcet (8), both of which were
found to be highly protective. Whether this route of adminis-
tration of AMB-lipid formulations will be well tolerated and
will be effective in human patients is not known, as only one
report on the use of nebulized AmBisome in a single patient
has been published (22).
In summary, a single dose of PEG-AMB-LIP (10 mg/kg) is
as effective as a 10-day treatment with AMB desoxycholate (1
mg/kg/dose) in significantly prolonging the survival of persis-
tently leukopenic rats infected with A. fumigatus. Unfortu-
nately, this observed delay in the progression of the infection
after antifungal treatment was not sufficient to keep the ani-
mals alive when the numbers of leukocytes in blood were
restored late in the course of infection.
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